tiprankstipranks
Advertisement
Advertisement
Connect Biopharma initiated with an Overweight at Piper Sandler
PremiumThe FlyConnect Biopharma initiated with an Overweight at Piper Sandler
2M ago
Buy Rating Reiterated on Connect Biopharma as Analyst Sees Underappreciated Rademikibart Upside; $7 Price Target Maintained
Premium
Ratings
Buy Rating Reiterated on Connect Biopharma as Analyst Sees Underappreciated Rademikibart Upside; $7 Price Target Maintained
2M ago
Canaccord sees potential Apogee buyout as ‘huge win’ for sector
Premium
The Fly
Canaccord sees potential Apogee buyout as ‘huge win’ for sector
2M ago
Analyst Reiterates Buy on Rademikibart, Citing Strong Clinical Profile, Large Market Opportunity and Unchanged $10 Price Target
PremiumRatingsAnalyst Reiterates Buy on Rademikibart, Citing Strong Clinical Profile, Large Market Opportunity and Unchanged $10 Price Target
3M ago
Connect Biopharma reports Q1 EPS (34c), consensus (28c)
Premium
The Fly
Connect Biopharma reports Q1 EPS (34c), consensus (28c)
3M ago
Connect Biopharma Advances Rademikibart After Positive Interim Review
Premium
Company Announcements
Connect Biopharma Advances Rademikibart After Positive Interim Review
4M ago
Connect Biopharma Highlights Positive Rademikibart Respiratory Trial Results
PremiumCompany AnnouncementsConnect Biopharma Highlights Positive Rademikibart Respiratory Trial Results
5M ago
Connect Biopharma announces results from rademikibart study
Premium
The Fly
Connect Biopharma announces results from rademikibart study
5M ago
CNTB Earnings Report this Week: Is It a Buy, Ahead of Earnings?
Premium
Pre-Earnings
CNTB Earnings Report this Week: Is It a Buy, Ahead of Earnings?
5M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100